# RDY catalysts: DR REDDYS LABORATORIES LTD PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/rdy/catalysts

> DR REDDYS LABORATORIES LTD (RDY) has 1 upcoming catalyst. The next is the Orencia (abatacept) PDUFA date, Dec 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | DR REDDYS LABORATORIES LTD |
| Ticker | RDY (NYSE) |
| SEC CIK | 1135951 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/rdy |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 17, 2014 | [VELCADE® (bortezomib) complete response letter (CRL)](https://sec-api.dev/pdufa/bortezomib) | RDY |  | completed, complete response letter | "should specify We have completed our review of NDA 206927/Original 1 eM and have determined that we cannot approve these application(s) in their present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22206927_2019_Orig1s000OtherActionLtrs.pdf%22)) |
| May 4, 2016 | [VELCADE® (bortezomib) complete response letter (CRL)](https://sec-api.dev/pdufa/bortezomib) | RDY |  | completed, complete response letter | "We have completed our review of NDA 206927/Original 1 OM as amended, and have determined that we cannot approve these applications in their present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22206927_2019_Orig1s000OtherActionLtrs.pdf%22)) |
| August 30, 2016 | [Xeglyze (abametapir) complete response letter (CRL)](https://sec-api.dev/pdufa/abametapir) | RDY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22206966_2020_Orig1s000OtherActionLtrs.pdf%22)) |
| July 24, 2018 | [Cyclophosphamide (cyclophosphamide) complete response letter (CRL)](https://sec-api.dev/pdufa/cyclophosphamide) | RDY |  | completed, complete response letter | "We have completed our review of this application, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22210852_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| May 3, 2019 | [Cyclophosphamide (cyclophosphamide) complete response letter (CRL)](https://sec-api.dev/pdufa/cyclophosphamide) | RDY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22210852_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| October 4, 2019 | [VELCADE® (bortezomib) FDA approval](https://sec-api.dev/pdufa/bortezomib) | RDY |  | completed, approved | "NDA206927 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20191004, review_priority STANDARD; sponsor_name DR REDDYS; product BORTEZOMIB (BORTEZOMIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA206927%22)) |
| October 21, 2019 | [Biorphen (phenylephrine hydrochloride) FDA approval](https://sec-api.dev/pdufa/phenylephrine) | RDY |  | completed, approved | "NDA212909 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20191021, review_priority STANDARD; sponsor_name DR REDDYS LABS SA; product BIORPHEN (PHENYLEPHRINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212909%22)) |
| November 20, 2019 | [Cyclophosphamide (cyclophosphamide) complete response letter (CRL)](https://sec-api.dev/pdufa/cyclophosphamide) | RDY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22210852_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| May 21, 2020 | [Cyclophosphamide (cyclophosphamide) complete response letter (CRL)](https://sec-api.dev/pdufa/cyclophosphamide) | RDY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22210852_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| July 30, 2020 | [Cyclophosphamide (cyclophosphamide) FDA approval](https://sec-api.dev/pdufa/cyclophosphamide) | RDY |  | completed, approved | "NDA212501 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20200730, review_priority STANDARD; sponsor_name DR REDDYS; product CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212501%22)) |
| November 6, 2020 | [Cyclophosphamide (cyclophosphamide) complete response letter (CRL)](https://sec-api.dev/pdufa/cyclophosphamide) | RDY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined hat we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22210852_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| March 11, 2021 | [Biorphen (phenylephrine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/phenylephrine) | RDY |  | completed, approved | "NDA212909 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20210311, review_priority STANDARD; sponsor_name DR REDDYS LABS SA; product BIORPHEN (PHENYLEPHRINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212909%22)) |
| June 14, 2021 | [Rezipres (ephedrine hydrochloride) FDA approval](https://sec-api.dev/pdufa/ephedrine) | RDY |  | completed, approved | "NDA213536 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20210614, review_priority STANDARD; sponsor_name DR REDDYS LABS SA; product REZIPRES (EPHEDRINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213536%22)) |
| April 18, 2022 | [Cyclophosphamide (cyclophosphamide) complete response letter (CRL)](https://sec-api.dev/pdufa/cyclophosphamide) | RDY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22210852_2024_Orig1s000OtherActionLtrs.pdf%22)) |
| April 19, 2024 | [Zimrixby (rituximab-cdxx) complete response letter (CRL)](https://sec-api.dev/pdufa/rituximab-cdxx) | RDY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761376_20240419.pdf%22)) |
| Nov 2024 | [Biosimilar complete response letter (CRL)](https://sec-api.dev/pdufa/biosimilar) | RDY |  | completed, complete response letter | "In November 2024, the U.S. FDA issued a complete response letter ("CRL") with additional queries in reference to the ongoing resolution of observations arising from the October 2023 inspection, as well as certain aspects pertaining to our biologics license application ("BLA") for a biosimilar rituximab." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000381/rdy0899_20f.htm)) |
| Apr 2025 | [Biosimilar NDA/BLA submission](https://sec-api.dev/pdufa/biosimilar) | RDY |  | completed | "While we submitted a deficiency response letter for the CRL in April 2025, and resubmitted our BLA, there is no certainty on timelines as to when the U.S. FDA will ultimately approve our resubmitted BLA, or guaranty of such approval, and we could experience further delays relating to the development of the biosimilar product." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1135951/000157587225000393/rdy-20250331.htm)) |
| May 30, 2025 | [Biorphen (phenylephrine hydrochloride) FDA approval](https://sec-api.dev/pdufa/phenylephrine) | RDY |  | completed, approved | "NDA216830 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20250530, review_priority STANDARD; sponsor_name DR REDDYS LABS SA; product PHENYLEPHRINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE (PHENYLEPHRINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216830%22)) |
| Sep 2025 | [TRUXIMA® (rituximab) complete response letter (CRL)](https://sec-api.dev/pdufa/rituximab) | RDY |  | completed, complete response letter | "Received a CRL for rituximab biosimilar BLA, in reference to the ongoing resolution of observations arising from the Pre Approval Inspection (PAI) of our Biologics facility at Bachupally, Hyderabad, Telangana, India conducted in September 2025, as well as certain aspects pertaining to the BLA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000034/rdy0840_ex99-1.htm)) |
| October 16, 2025 | [Zimrixby (rituximab-cdxx) complete response letter (CRL)](https://sec-api.dev/pdufa/rituximab-cdxx) | RDY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761376_20251016.pdf%22)) |
| December 30, 2025 | [Avt03 complete response letter (CRL)](https://sec-api.dev/pdufa/avt03) | RDY |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_BLA761471_20251230.pdf%22)) |
| July 31, 2026 | [Zimrixby (rituximab-cdxx) FDA approval](https://sec-api.dev/pdufa/rituximab-cdxx) | RDY |  | completed, approved | "BLA761376 ORIG-1: submission_status AP, submission_status_date 20260731, review_priority STANDARD; sponsor_name DR REDDYS LABS SA; product ZIMRIXBY (RITUXIMAB-CDXX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761376%22)) |
| Dec 2026 | [Orencia (abatacept) PDUFA date](https://sec-api.dev/pdufa/abatacept) | RDY |  | scheduled | "As we speak today, the goal date for abatacept is in mid-December 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000536/rdy0931_ex99-1.htm)) |

## Drugs

- [Xeglyze (abametapir)](https://sec-api.dev/pdufa/abametapir): 
- [Avt03](https://sec-api.dev/pdufa/avt03): 
- [VELCADE® (bortezomib)](https://sec-api.dev/pdufa/bortezomib): 
- [Cyclophosphamide (cyclophosphamide)](https://sec-api.dev/pdufa/cyclophosphamide): 
- [Rezipres (ephedrine hydrochloride)](https://sec-api.dev/pdufa/ephedrine): 
- [Biorphen (phenylephrine hydrochloride)](https://sec-api.dev/pdufa/phenylephrine): 
- [Zimrixby (rituximab-cdxx)](https://sec-api.dev/pdufa/rituximab-cdxx): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/rdy/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RDY catalysts: DR REDDYS LABORATORIES LTD PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/rdy/catalysts

```bibtex
@misc{secapidev_companies_rdy_catalysts_20261116,
  title        = {RDY catalysts: DR REDDYS LABORATORIES LTD PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/rdy/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_rdy_catalysts_20261116","title":"RDY catalysts: DR REDDYS LABORATORIES LTD PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/rdy/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
